FDA Approves Dendreon's drug
Provenge would treat prostate cancer; stock rockets upward.
Dendreon's prostate cancer treatment Provenge won much-coveted approval from the U.S. Food and Drug Association today. The company's stock (Nasdaq: DNDN) is up 15 percent after the mid-day announcement.
Share this Blog
Comments
Post new comment